<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390817</url>
  </required_header>
  <id_info>
    <org_study_id>wakeup01</org_study_id>
    <nct_id>NCT02390817</nct_id>
  </id_info>
  <brief_title>Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup</brief_title>
  <official_title>Effect of Sugammadex in Wakeup Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cukurova University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortopedia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cukurova University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be performed to evaluate motor response and awareness with using sugammadex
      during wakeup procedure in spine surgery. The investigator's goal is to investigate the
      effect of sugammadex on the state of consciousness and motor-somatosensorial evoked
      potentials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between 10-25 age, American Society of Anesthesiologist clinical status(ASA) I-II, 60 patient
      which will be performed spine surgery in orthopedics clinic will be enrolled in this study.
      Patient will be randomized into two group that include 20 patient. General anesthesia will be
      administered by Totally intravenous anesthesia (TIVA) with propofol and remifentanyl for all
      patients. Two groups will be monitored with BIS (bispectral index), TOF (train-of-for) MEP
      (motor evoked potential) and SSEP (somatosensorial potential). During wakeup procedure, in
      group S, TIVA will be stopped and 2 mg/kg of sugammadex will be given intravenously. BIS,
      TOF, MEP, SSEP will be measured. In group N, TIVA will be stopped and 0.04 mg/kg of
      neostigmine will be given. Also BIS, TOF, MEP, SSEP will be measured. Sugammadex will be
      given group S and Neostigmine will be given group N at the end of the operation. At
      postoperative sixth hour, the investigators will visit all the patients and ask standard
      questions about intraoperative wakeup procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to consciousness</measure>
    <time_frame>30 min</time_frame>
    <description>time to obeying verbal commands after reversal of NMBAs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess Motor Evoked Potential values</measure>
    <time_frame>4 hours</time_frame>
    <description>Motor Evoked Potential (MEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess Somatosensorial Evoked Potential values</measure>
    <time_frame>4 hours</time_frame>
    <description>Somatosensorial Evoked Potential (SSEP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Spinal Curvatures</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the wakeup status Sugammadex 2 mg/kg single dose will perform.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Administration of Sugammadex</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>group I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Administration of Neostigmine</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>group II</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American society of anesthesiologists (ASA) physical status I-II patients

          -  spine surgery

          -  10-25 age

        Exclusion Criteria:

          -  ASA III and above

          -  Patient refusal

          -  neuromuscular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebru Biricik</last_name>
    <role>Study Director</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ebru Biricik</name>
      <address>
        <city>Adana</city>
        <state>Sarıçam</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Çukurova University</name>
      <address>
        <city>Adana</city>
        <state>Çukurova</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://pubmed.gov</url>
    <description>full text</description>
  </link>
  <reference>
    <citation>Adamus M, Hrabalek L, Wanek T, Gabrhelik T, Zapletalova J. Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. J Anesth. 2011 Oct;25(5):716-20. doi: 10.1007/s00540-011-1209-1. Epub 2011 Aug 13.</citation>
    <PMID>21842171</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cukurova University</investigator_affiliation>
    <investigator_full_name>ebru biricik</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Curvatures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

